Organogenesis Holdings Inc. Q1 FY2025 earnings call

Gary began by discussing first quarter revenue results, noting they were in line with guidance despite customer demand disruption due to LCD uncertainty. He highlighted CMS's delay of LCD implementation, applauded CMS's focus on coverage with clinical efficacy, and emphasized the importance of real-world evidence. He also provided updates on the renew program, clinical validation of wound care solutions, and manufacturing expansion. Dave then reviewed financial results, mentioning net revenue, gross profit, operating expenses, and provided 2025 guidance, including revenue range, gross margin expectations, and modeling considerations.

Net revenue for the first quarter was $86.7 million, down 21%. Advanced wound care net revenue for the first quarter was $79.9 million, down 23%. Net revenue from Surgical and Sports Medicine products for the first quarter was $6.8 million, up 11%. Gross profit for the first quarter was $63 million or 72.6% of net revenue compared to 73.9% last year.

For 2025, net revenue is expected to be between $480 million and $535 million. GAAP net income is in the range of $4.7 million to $34 million, and EBITDA is in the range of $20 million to $59.6 million. Non-GAAP adjusted net income is unchanged at $15.3 million to $44.6 million, and adjusted EBITDA is unchanged at $43.6 million to $83.2 million. Second-quarter revenue is expected to be in the range of approximately $100 million to $110 million. Gross margin is expected to be in the range of approximately 78% to 79%.

Risks include market uncertainty related to CMS's LCD implementation, potential delays or changes in coverage policies, and competition dynamics affecting revenue and margin performance.

Q: Brooks O'Neil of Lake Capital Markets asked about the cadence of the year and confidence in guidance.

A: Dave Francisco responded discussing optionality in the portfolio, reaffirming guidance, and mentioned gross margin being back-end loaded due to mix shift and inventory expiry.

Q: Ryan Zimmerman of BTIG asked about why the fourth quarter strong performance didn't repeat in the first quarter.

A: Gary Gillheeney explained differences in market dynamics, confusion, and audits affecting customer buying behavior.

Q: Ross Osborne of Cantor Fitzgerald asked about guidance reiteration despite LCD delay.

A: Gary Gillheeney and Dave Francisco discussed portfolio optionality, mix shift to higher margin products, and stabilization of market and customer behavior in the back half.